+91-8668442535

Alpha Mannosidosis Market By Indication Type (Type I, Type II, Type III), By Treatment (Bone Marrow Treatment, Enzyme Replacement Treatment) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Aplha mannosidosis is a rare genetic disorder belonging to a group of diseases known as lysosomal storage disorders. Alpha mannosidosis occurs in 1 in every 500,000 people in the general population and is characterized by a deficiency of the enzyme alpha-D-mannosidase. The symptoms, progression, and severity of alpha-mannosidosis vary widely from one person to another, including between siblings who share the same mutation.

The report titled "Global Alpha Mannosidosis Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the alpha mannosidosis market along with the market size and estimates for the duration of 2017–2025. The research study covers an in-depth analysis of market segments based on indication type, treatment, and different geographical regions.

The report also includes sections on the competitive profiling of the leading players in the global alpha mannosidosis market, appealing investment propositions, and market positioning of key manufacturers to assist strategic decision-makers.

Geographically, the global alpha mannosidosis market is studied for the following regional markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • rest of Latin America
  • Middle East and Africa
  • GCC
  • the remainder of MEA

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global alpha mannosidosis market. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive scenario of the global alpha mannosidosis market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global alpha mannosidosis market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global alpha mannosidosis market, offering market size and estimates for the period from 2017 to 2025, keeping in mind the above-mentioned factors.

Based on the type of indication, the global alpha mannosidosis market is segmented as follows:

  • Type I
  • Type II
  • Type III

Aplha mannosidosis is a rare genetic disorder belonging to a group of diseases known as lysosomal storage disorders. Aplha mannosidosis occurs in 1 in every 500,000 people in the general population and is characterized by a deficiency of the enzyme alpha-D-mannosidase. The symptoms, progression, and severity of alpha-mannosidosis vary widely from one person to another, including between siblings who share the same mutation. The commonly seen signs of dysfunction in people with alpha mannosidosis include intellectual disability, skeletal abnormalities, and distinctive facial features. The global alpha mannosidosis market is segmented into three separate subtypes, such as mild (type I), moderate (type II), and severe (type III). The type II indication held the largest share in the global alpha mannosidosis market due to the high prevalence of type II alpha mannosidosis. The Type II indication is expected to grow during the forecast period due to the rising prevalence of alpha-mannosidase. Furthermore, ongoing clinical trials for the treatment of alpha mannosidosis will propel the market during the forecast period.

Based on the type of treatment, the alpha mannosidosis market is segmented into:

  • Bone Marrow Transplant (BMT)
  • Enzyme Replacement Therapy (ERT)

Alpha-mannosidosis is one of several diseases known as lysosomal storage disorders. The prevalence of alpha-mannosidosis is estimated to be 1 in every 500,000 people in the general population. Alpha-mannosidosis affects men and women in equal numbers and can potentially affect individuals of any ethnic group worldwide. The treatment option for alpha mannosidosis is symptomatic and supportive. The alpha mannosidosis market has been divided into two segments based on treatment: bone marrow treatment and enzyme replacement therapy. A bone marrow treatment is under clinical trial for the treatment of alpha mannosidosis. However, the BMT procedure is expensive and carries the risk of serious complications, including graft-versus-host disease and other long-term effects. Enzyme replacement therapy involves replacing a missing enzyme in individuals who are deficient in or lack the particular enzyme in question. Lazy, an enzyme replacement therapy, is in the late stages of clinical trials as a potential treatment for individuals with alpha-mannosidosis. Moreover, gene therapy is also being studied as another possible approach to therapy for some lysosomal storage disorders.

For the purpose of this study, the global alpha mannosidosis market is categorized as follows:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

For the purpose of this study, the global alpha mannosidosis market is segmented into regional markets such as North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America held the largest share of the alpha mannosidosis market due to increased clinical trials in the region. After the Orphan Drugs Act was passed in the U.S., the development and approval of drugs for orphan diseases have escalated. As a result, it has emerged as the biggest benefit for pharmaceutical companies to launch orphan drugs on a fast-track basis. The ERT drug for alpha mannosidosis, named Lamazym, has also been given orphan drug status across Europe and the U.S. Asia Pacific and is projected to grow at the fastest rate during the forecast period. The growth will be attributed to the rising awareness of the disease in developing countries. The Government of Australia has implemented a national plan for helping patients with rare diseases to reduce the mortality rate due to these diseases. The plan aims to raise awareness about the burden of rare diseases among patients, their impact on social life, and healthcare professionals.

Frequently Asked Questions: 

The market for Alpha Mannosidosis is expected to reach US$ 23.9 Mn in 2025.

The Alpha Mannosidosis market is expected to see significant CAGR growth over the coming years, at 17.2%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Zymenex (Chiesi Farmaceutici S.p.A) are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Oct 2018
Category:  Pharmaceuticals
Report ID:   58561
Report Format:   PDF
Pages:   120
Rating:    4.7 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support